Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trial Research
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
November 22nd, 2008
Repligen Corporation (NASDAQ:RGEN) reported results for the second quarter of fiscal year 2009, ended September 30, 2008. Total revenue for the quarter was $5,090,000 compared to total revenue of $5,352,000 for the second quarter of fiscal year 2008 ended September 30, 2007. Total revenue was comprised of product revenue and royalty and research revenue. Product revenue, comprised of Protein A revenue, for the second quarter of fiscal year 2009 was $2,984,000 and royalty and research revenue was $2,106,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R). Operating expenses for the second quarter of fiscal year 2009 were...
Source: Law & Health Weekly (2008-11-22)
|
